Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients
Comparison in people · 2022
- What was studied
- 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
- Main finding
- In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
Moderate disease · duration · 14 ± 1.9 vs 16 ± 2.2 days · Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4.
Reported findings and study design
Each severity stratum had 12 patients per arm. Only the acute moderate combination included Vladonix. All patients received standard care.
Population or model 48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
Dose, route and schedule
Moderate disease: Vladonix one capsule twice daily during illness with intranasal interferon alfa-2b and Roncoleukin (500,000 IU for 6–8 days). Acute mild disease received interferon and Roncoleukin without Vladonix. The post-COVID sections describe Vladonix for 10 or 30 days alongside Roncoleukin. Capsule peptide mass is unspecified.
Protocol source ↗ · Original journal PDF, methods and Table 1
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Moderate disease · duration | 14 ± 1.9 vs 16 ± 2.2 days | Adjunct combination versus standard care, Table 1. The text gives 14.2 ± 2.2 vs 16.2 ± 2.4. |
| Moderate disease · post-COVID symptoms | 3/12 vs 7/12 | Adjunct combination versus standard care. Recovery among these patients averaged 32.2 vs 36.2 days. |
| Worsening and reported adverse effects | No cases reported | No group-level adverse-event table or systematic assessment method is provided. |
Table 1 · illness duration and post-COVID cases
| Group | n | Illness (days) | Post-COVID cases | Recovery (days) |
|---|---|---|---|---|
| Mild · interferon + IL-2 | 12 | 8 ± 1.2 | 0 | — |
| Mild · usual care | 12 | 10 ± 1.8 | 1 | 28 |
| Moderate · Vladonix + interferon + IL-2 | 12 | 14 ± 1.9 | 3 | 32.2 |
| Moderate · usual care | 12 | 16 ± 2.2 | 7 | 36.2 |
Table 1 means are used for acute illness. For moderate post-COVID recovery the prose gives ±4.5 and ±4.1 days, respectively. The corresponding table uncertainty fields are malformed.
The four small groups tested severity-specific combinations. They do not establish a separate Vladonix effect.
Source for these results ↗ · Reviewed 2026-11-13
Study limitations and source details
Study limitations
- Group assignment and masking are unclear. The combination prevents attribution to Vladonix alone.
- The illness-duration means differ slightly between Table 1 and the narrative. Post-COVID criteria and systematic adverse-event collection are not described.
Source details
Original journal article
Original journal PDF, methods and Table 1
Sources checked
Added to the library
Citation
N. Serikov, A. Zinatollayeva, Z. Karimova, N. K. Kudaibergenova, G. Zh. Abdrakhmanova, D. B. Kozubaeva, F. F. Yagofarov. Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients Terapevt. 2022(4):34–39
Study source ↗ · DOI 10.33920/MED-12-2204-04 · Bibliography entry · Link to this summary